Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
G. Lyrarakis,
S. Bouros,
A. Anastasopoulou,
A. Gkoufa,
P. Diamantopoulos,
H. Gogas,
D. Ziogas
Affiliations
G. Lyrarakis
National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
S. Bouros
National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
A. Anastasopoulou
National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
A. Gkoufa
National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
P. Diamantopoulos
National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
H. Gogas
National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
D. Ziogas
National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
